Syntara the science explained, page-44

Hi all,

A quick look at SNT-5382. ( Syntara)

SNT-5382, a selective lysyl oxidase-like 2 inhibitor developed for the treatment of chronic fibrosis in a number of organs.

So how does a selective lysl oxidase-like 2 inhibitor work in laypersons terms.

https://pubmed.ncbi.nlm.nih.gov/28073888/

This type of inhibitor works by blocking the activity of the LOXL2 enzyme, which plays a key role in the formation and stabilization of fibrotic tissue (excessive scarring) in various organs and diseases.

So how does chronic fibrosis start ?

Chronic fibrosis arises from an abnormal wound healing response, where the initial inflammatory and repair mechanisms become dysregulated, leading to excessive scarring and permanent tissue remodeling, often driven by persistent injury or inflammation.

LOXL2 is responsible for crosslinking collagen and elastin fibers, making the extracellular matrix (the structural support surrounding cells) more rigid and resistant to degradation.

So by inhibiting the LOXL2 it reduces underlying scarring and reduced formation of fibrotic tissue.

Without LOXL2 activity, newly formed collagen fibers remain uncrosslinked and more susceptible to degradation, preventing the buildup of rigid scar tissue.

By disrupting the crosslinks in already formed fibrotic tissue, the inhibitor can help break down and remodel the excessive scarring, promoting tissue repair and regeneration.

Ok so how can a person with no co morbidities acquire chronic lung fibrosis ?

Fibrosis occurs without any known underlying cause or associated condition. It typically affects older adults, with a median age at diagnosis of around 65-70 years old. The exact etiology is unknown, but it is believed to involve an abnormal wound healing response in the lungs, leading to excessive deposition of collagen and other extracellular matrix proteins, ultimately resulting in progressive lung scarring and impaired gas exchange.

Approximately 1 million plus patients worldwide per year.

https://pubmed.ncbi.nlm.nih.gov/34233665/

Syntara has successfully completed an early-stage safety and pharmacology study for SNT-5382, supporting its continued development as a potential anti-fibrotic therapy.

More to come on Syntara compounds.

Kpax